@jutawansenyap I can ask you the same thing. Why did ENCIK TAUFIQ AHMAD @ AHMAD MUSTAPHA BIN GHAZALI, the executive director keep on selling his shares for Prlexus??? You knew that yet you enter Prlexus...So dont come here and act smart LOL

If you see my post above, it is not mr wu wai kong calling the shots. The executive director Steven Kuah is the one calling the shots and making all the business deals and agreements. Mr Wu wants to sell it is up to him. Perhaps he wants to pay off his bills or diversify his portfolio or buy a christmas present. There are 1001 reasons why.

@jutawansenyap Lol what a moron calling others moron when he is losing money from his facemask and glove stocks LOLOLOL

@jutawansenyap Really pity you and your facemask and glove counters. Already lose money come here and bark everyday because you are unhappy LOL

@Jutawansenyap If you notice i never promote directly. I only share news articles. Once a liar always a liar LOL Better stop lying or else god will punish you kekeke

@Jutawansenyap So you are saying all those news articles are false? Once stupid always stupid. Your stupidity is incurable LOL

@Jutawansenyap Aiyoyo pity your Esceram, Prelexus and Topglove...kekeke

@Jutawansenyap Go back to your facemask and glove counters LOL It is already game over for you LOL That why come to vaccine counter buat kacau kekeke

@jutawansenyap LOL Stupid shark over here. From day one already damn stupid. Coming here to bark everyday...LOL

@jutawansenyap Whats your ulterior motive here everyday? Such a misleading person LOL

@jutawansenyap Once a dick always a dick...Thats what you are...kekeke

@jutawansenyap What the hell are you talking about misleading info. I was only sharing news articles. Dont be a dick.

China Prepares Large-Scale Rollout of Covid-19 Vaccines

One developer, China National Pharmaceutical Group, known as Sinopharm, said in November it applied for final market approval for use of its vaccine in China. Others have been approved for emergency use on people deemed at high risk of infection.

“We must be prepared for large-scale production,” said Vice Premier Sun Chunlan, who has overseen much of the country's response, during a visit Wednesday to developers, according to the official Xinhua News Agency.

The government has yet to say how many people it plans to vaccinate. Sun said plans call for vaccinating border personnel and other high-risk populations this month.

Sinopharm has clinical trials under way in 10 countries including the United Arab Emirates, Egypt, Jordan, Peru and Argentina with nearly 60,000 volunteers. It has built two facilities in China capable of producing 200 million doses per year.

https://www.bloomberg.com/news/articles/2020-12-06/china-prepares-large-scale-rollout-of-covid-19-vaccines

China Prepares Large-Scale Rollout of Covid-19 Vaccines

One developer, China National Pharmaceutical Group, known as Sinopharm, said in November it applied for final market approval for use of its vaccine in China. Others have been approved for emergency use on people deemed at high risk of infection.

“We must be prepared for large-scale production,” said Vice Premier Sun Chunlan, who has overseen much of the country's response, during a visit Wednesday to developers, according to the official Xinhua News Agency.

The government has yet to say how many people it plans to vaccinate. Sun said plans call for vaccinating border personnel and other high-risk populations this month.

Sinopharm has clinical trials under way in 10 countries including the United Arab Emirates, Egypt, Jordan, Peru and Argentina with nearly 60,000 volunteers. It has built two facilities in China capable of producing 200 million doses per year.

https://www.bloomberg.com/news/articles/2020-12-06/china-prepares-large-scale-rollout-of-covid-19-vaccines

http://malaysiansmustknowthetruth.blogspot.com/2020/12/health-ministry-to-seek-info-on-pfizer.html

https://www.malaysiakini.com/news/554000

MOH: NPRA yet to receive Covid-19 vaccine evaluation registration document from Pfizer

KUALA LUMPUR (Dec 6): The Ministry of Health's (MOH) National Pharmaceutical Regulatory Agency (NPRA) has so far not received any documents from Pfizer for evaluation registration and testing of the Covid-19 vaccine, said Health director-general Tan Sri Dr Noor Hisham Abdullah.

He said the ministry has no direct information on whether there have been some problems in the supply of the vaccine as reported by a foreign media agency.

"The Health Ministry, however, will monitor developments on Pfizer's Covid-19 vaccine and obtain more information on the matter.

"The ministry will notify the public on developments from time to time," he said in a statement today.

Dr Noor Hisham was commenting on a Reuters report on Dec 4 which, among others, said that the pharmaceutical company might not be able to meet its production target for the vaccine for 2020 due to a lack of raw materials.

https://www.theedgemarkets.com/article/moh-npra-yet-receive-covid19-vaccine-evaluation-registration-document-pfizer

@UlarSawa Sinopharm vaccine storage temperature is 2-8C

-------------

A main concern with European vaccines is the temperature they have to be stored, however, Sinopharm’s Covid-19 vaccines can be transported and stored at normal fridge temperatures of 2 to 8 degrees Celsius. This is a big plus on the Chinese vaccine, to handle distribution and storage, Kanger will work with Zuellig Pharma who incidentally is the the largest vaccine distributor in Malaysia and Asia.

https://www.businesstoday.com.my/2020/11/23/kanger-international-moves-from-bamboo-flooring-to-covid-19-vaccine-distribution/

Pfizer shares fall on report company cut its Covid vaccine rollout target

Pfizer shares fell Thursday after a report said the U.S. drugmaker expects to ship half of the Covid-19 vaccines it originally planned for this year due to supply-chain problems.

The company has repeatedly said publicly that it planned to ship 50 million vaccine doses this year and up to 1.3 billion doses by the end of 2021.

The Wall Street Journal, citing a person directly involved in the development, said some early batches of the raw materials needed for the vaccine failed to meet standards. Pfizer now plans to ship 50 million vaccines by the end of the year, down from the original 100 million it had hoped to send out, according to the Journal.

https://www.cnbc.com/2020/12/03/pfizer-shares-fall-on-report-company-cut-its-covid-vaccine-rollout-target.html
-----------------------------

Pfizer Scaled Back 2020 COVID-19 Vaccine Production Targets From 100 Million to 50 Million Doses

Pfizer scaled back its Covid-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.

In news releases through September, Pfizer had said that it aimed to manufacture up to 100 million vaccine doses this year. But in several releases in November, the company cut that to an estimate of up to 50 million doses. Pfizer is developing its vaccine with Germany-based BioNTech SE.

A Pfizer spokeswoman said in a statement Thursday that multiple factors slowed the company down, including the time it took to source large quantities of the raw materials needed to produce the shots. But the company said it has finished bringing its manufacturing up to scale and it is now producing vaccines at a rapid pace.

https://time.com/5917847/pfizer-cut-covid-19-vaccine-targets/

Pfizer shares fall on report company cut its Covid vaccine rollout target

Pfizer shares fell Thursday after a report said the U.S. drugmaker expects to ship half of the Covid-19 vaccines it originally planned for this year due to supply-chain problems.

The company has repeatedly said publicly that it planned to ship 50 million vaccine doses this year and up to 1.3 billion doses by the end of 2021.

The Wall Street Journal, citing a person directly involved in the development, said some early batches of the raw materials needed for the vaccine failed to meet standards. Pfizer now plans to ship 50 million vaccines by the end of the year, down from the original 100 million it had hoped to send out, according to the Journal.

https://www.cnbc.com/2020/12/03/pfizer-shares-fall-on-report-company-cut-its-covid-vaccine-rollout-target.html
-----------------------------

Pfizer Scaled Back 2020 COVID-19 Vaccine Production Targets From 100 Million to 50 Million Doses

Pfizer scaled back its Covid-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.

In news releases through September, Pfizer had said that it aimed to manufacture up to 100 million vaccine doses this year. But in several releases in November, the company cut that to an estimate of up to 50 million doses. Pfizer is developing its vaccine with Germany-based BioNTech SE.

A Pfizer spokeswoman said in a statement Thursday that multiple factors slowed the company down, including the time it took to source large quantities of the raw materials needed to produce the shots. But the company said it has finished bringing its manufacturing up to scale and it is now producing vaccines at a rapid pace.

https://time.com/5917847/pfizer-cut-covid-19-vaccine-targets/

EU criticises ‘hasty’ UK approval of COVID-19 vaccine
European Medicines Agency says its approval process is more appropriate, as German politician calls UK move ‘problematic’.

European regulators have issued caution over the United Kingdom’s move to approve Pfizer-BioNTech’s COVID-19 vaccine for widespread use, saying their longer approval process was safer.

In an unusually blunt statement, the European Medicines Agency (EMA), which is in charge of approving COVID-19 vaccines for the EU, said its longer approval procedure was more appropriate as it was based on more evidence and required more checks than the emergency procedure chosen by the UK.

A spokesman for the European Commission, the EU executive, said the EMA’s procedure was “the most effective regulatory mechanism to grant all EU citizens’ access to a safe and effective vaccine,” as it was based on more evidence.

The EMA’s comments came hours after the UK became the first country in the world to approve the drug developed by Pfizer and BioNTech for use.

Peter Liese, an EU legislator and member of German Chancellor Angela Merkel’s Christian Democratic Union party, struck a firmer tone, saying he considered the MHRA’s approval to be “problematic”.

“I recommend that EU member states do not repeat the process in the same way,” he said.

“A few weeks of thorough examination by the European Medicines Agency (EMA) is better than a hasty emergency marketing authorisation of a vaccine.”

https://www.aljazeera.com/news/2020/12/2/eu-criticises-hasty-uk-approval-of-covid-19-vaccine

EU criticises ‘hasty’ UK approval of COVID-19 vaccine
European Medicines Agency says its approval process is more appropriate, as German politician calls UK move ‘problematic’.

European regulators have issued caution over the United Kingdom’s move to approve Pfizer-BioNTech’s COVID-19 vaccine for widespread use, saying their longer approval process was safer.

In an unusually blunt statement, the European Medicines Agency (EMA), which is in charge of approving COVID-19 vaccines for the EU, said its longer approval procedure was more appropriate as it was based on more evidence and required more checks than the emergency procedure chosen by the UK.

A spokesman for the European Commission, the EU executive, said the EMA’s procedure was “the most effective regulatory mechanism to grant all EU citizens’ access to a safe and effective vaccine,” as it was based on more evidence.

The EMA’s comments came hours after the UK became the first country in the world to approve the drug developed by Pfizer and BioNTech for use.

Peter Liese, an EU legislator and member of German Chancellor Angela Merkel’s Christian Democratic Union party, struck a firmer tone, saying he considered the MHRA’s approval to be “problematic”.

“I recommend that EU member states do not repeat the process in the same way,” he said.

“A few weeks of thorough examination by the European Medicines Agency (EMA) is better than a hasty emergency marketing authorisation of a vaccine.”

https://www.aljazeera.com/news/2020/12/2/eu-criticises-hasty-uk-approval-of-covid-19-vaccine

All the other vaccine counters already goreng, so it is only a matter of time for Kanger....

Its literally game over for face mask and gloves. The sentiment has died. Ppl cant wait to return to their normal lives...

https://fortune.com/2020/12/05/china-covid-19-vaccines-approval-sinovac-sinopharm/

How China’s COVID-19 could fill the gaps left by Pfizer, Moderna, AstraZeneca

But amid the optimism, experts have raised some concerns about the accessibility of Pfizer and Moderna's candidates, which require costly cold-chain distribution mechanisms, and about the quality of the data provided by British vaccine maker AstraZeneca.

At the same time, China's two leading vaccine makers—the private Sinovac and state-owned Sinopharm—appear close to rolling out their vaccines in coming weeks with candidates that don't require expensive cold chain networks.

Western vaccine makers appear to have taken the lead in the global race to produce a vaccine, but Chinese vaccine makers may help fill in the gaps they leave behind.

Still, Pfizer and Moderna’s vaccines are based on newly-developed mRNA technology that requires the candidates to be kept at sub-zero temperatures during shipments. Such temperature restrictions will make it difficult for lower- and middle-income countries to access the vaccines because they will need cold-storage infrastructure to distribute the doses.

In Indonesia, for example, the country's state-owned vaccine manufacturer Bio Farma said that Indonesia, the world's fourth-most populous nation, effectively cannot purchase Pfizer's vaccine given the logistical challenges in distributing it.

"Indonesia does not have such [cold-chain] capabilities, and it is hazardous if this vaccine is not stored at the proper temperature," Honesti Basyir, head Bio Farma, told Indonesian news outlet the Jakarta Globe on Nov. 22. In India, the country's 28,000-unit cold chain network used for distributing vaccines only handles vaccines between 2 and 8 degrees Celsius.

But in the days after AstraZeneca’s announcement, experts raised questions over the "transparency and rigor" of AstraZeneca’s data. Scientists questioned why the most effective results emerged from an apparent dosing error, and how datasets from multiple countries were combined and tabulated into the final results. In response, a spokesperson for AstraZeneca said its trials were conducted to the "highest standards." Still, amid the questions over its trial data, AstraZeneca CEO Pascal Soriot pledged that the company would conduct an additional study to validate its results

AstraZeneca’s woes and the potential distribution limitations of the Pfizer and Moderna vaccines have left a hole in the global supply that may be filled by Chinese vaccine makers, says Yanzhong Huang, senior fellow for global health at the Council on Foreign Relations.

Sinovac and Sinopharm, China’s two leading vaccine makers, are currently testing three vaccine candidates in phase III trials with candidates that could be distributed without cold storage chains. Sinovac's candidate, called CoronaVac, uses inactivated forms of COVID-19 to induce immune responses. Sinopharm's two unnamed candidates are both based on similar technology.

Beijing "absolutely" sees these Chinese-made vaccines as a potential substitution for AstraZeneca's candidate, says Huang. In state media outlets, Beijing is presenting Sinovac and Sinopharm's candidates as "particularly attractive to lower and middle income countries, especially the ones who cannot afford or don't have the capacity to sustain cold chain to distribute vaccines," Huang says.

Because they rely on inactivated forms of the virus, Sinovac's and Sinopharm's candidates are more stable in comparison to vaccines based on mRNA technology, meaning they don't need to be kept quite as cold. Similar to AstraZeneca, Sinovac says its vaccine can be stored and shipped at temperatures ranging from 2 to 8 degrees Celsius. Chinese state media reports that Sinopharm's candidates can likely be stored at a similar 2 to 8 degree Celsius range. Sinopharm declined Fortune's request for confirmation.

Admiral Craig Fuller, the U.S.'s top commander in Central and South America, told reporters this week that while the U.S. is focused "on taking care of the U.S. first," China is poised to deploy its vaccines around the world.

Still, Sinopharm may have a built-in edge given its established distribution networks within China and the fact that it is testing its vaccine in a broader array of countries than other Chinese vaccine makers.

"[Sinopharm's] large scale rollout [via China's emergency use program] also means that there is already a large distribution system, which has already been stress-tested," says Nicholas Thomas, a vaccine expert and health governance professor at the City University of Hong Kong. "This is a major advantage in the future distribution." Sinopharm is also already distributing vaccines to the United Arab Emirates via that country's emergency use program, and is testing, or plans to conduct trials, in at least ten countries including Egypt, Jordan, and Argentina.

https://fortune.com/2020/12/05/china-covid-19-vaccines-approval-sinovac-sinopharm/

How China’s COVID-19 could fill the gaps left by Pfizer, Moderna, AstraZeneca

But amid the optimism, experts have raised some concerns about the accessibility of Pfizer and Moderna's candidates, which require costly cold-chain distribution mechanisms, and about the quality of the data provided by British vaccine maker AstraZeneca.

At the same time, China's two leading vaccine makers—the private Sinovac and state-owned Sinopharm—appear close to rolling out their vaccines in coming weeks with candidates that don't require expensive cold chain networks.

Western vaccine makers appear to have taken the lead in the global race to produce a vaccine, but Chinese vaccine makers may help fill in the gaps they leave behind.

Still, Pfizer and Moderna’s vaccines are based on newly-developed mRNA technology that requires the candidates to be kept at sub-zero temperatures during shipments. Such temperature restrictions will make it difficult for lower- and middle-income countries to access the vaccines because they will need cold-storage infrastructure to distribute the doses.

In Indonesia, for example, the country's state-owned vaccine manufacturer Bio Farma said that Indonesia, the world's fourth-most populous nation, effectively cannot purchase Pfizer's vaccine given the logistical challenges in distributing it.

"Indonesia does not have such [cold-chain] capabilities, and it is hazardous if this vaccine is not stored at the proper temperature," Honesti Basyir, head Bio Farma, told Indonesian news outlet the Jakarta Globe on Nov. 22. In India, the country's 28,000-unit cold chain network used for distributing vaccines only handles vaccines between 2 and 8 degrees Celsius.

But in the days after AstraZeneca’s announcement, experts raised questions over the "transparency and rigor" of AstraZeneca’s data. Scientists questioned why the most effective results emerged from an apparent dosing error, and how datasets from multiple countries were combined and tabulated into the final results. In response, a spokesperson for AstraZeneca said its trials were conducted to the "highest standards." Still, amid the questions over its trial data, AstraZeneca CEO Pascal Soriot pledged that the company would conduct an additional study to validate its results

AstraZeneca’s woes and the potential distribution limitations of the Pfizer and Moderna vaccines have left a hole in the global supply that may be filled by Chinese vaccine makers, says Yanzhong Huang, senior fellow for global health at the Council on Foreign Relations.

Sinovac and Sinopharm, China’s two leading vaccine makers, are currently testing three vaccine candidates in phase III trials with candidates that could be distributed without cold storage chains. Sinovac's candidate, called CoronaVac, uses inactivated forms of COVID-19 to induce immune responses. Sinopharm's two unnamed candidates are both based on similar technology.

Beijing "absolutely" sees these Chinese-made vaccines as a potential substitution for AstraZeneca's candidate, says Huang. In state media outlets, Beijing is presenting Sinovac and Sinopharm's candidates as "particularly attractive to lower and middle income countries, especially the ones who cannot afford or don't have the capacity to sustain cold chain to distribute vaccines," Huang says.

Because they rely on inactivated forms of the virus, Sinovac's and Sinopharm's candidates are more stable in comparison to vaccines based on mRNA technology, meaning they don't need to be kept quite as cold. Similar to AstraZeneca, Sinovac says its vaccine can be stored and shipped at temperatures ranging from 2 to 8 degrees Celsius. Chinese state media reports that Sinopharm's candidates can likely be stored at a similar 2 to 8 degree Celsius range. Sinopharm declined Fortune's request for confirmation.

Admiral Craig Fuller, the U.S.'s top commander in Central and South America, told reporters this week that while the U.S. is focused "on taking care of the U.S. first," China is poised to deploy its vaccines around the world.

Still, Sinopharm may have a built-in edge given its established distribution networks within China and the fact that it is testing its vaccine in a broader array of countries than other Chinese vaccine makers.

"[Sinopharm's] large scale rollout [via China's emergency use program] also means that there is already a large distribution system, which has already been stress-tested," says Nicholas Thomas, a vaccine expert and health governance professor at the City University of Hong Kong. "This is a major advantage in the future distribution." Sinopharm is also already distributing vaccines to the United Arab Emirates via that country's emergency use program, and is testing, or plans to conduct trials, in at least ten countries including Egypt, Jordan, and Argentina.

lol what is @eyeHunter still doing here... i thought he is not interested in Kanger...weirdo...

Kanger should announce the investor for the private placement. Only question is when....

@UlarSawa The only reason Pfizer and Moderna vaccine is faster is due to the huge number of Covid cases in USA. Hence they are able to collect and analyse the data faster.

@UlarSawa It is not a requirement to conduct local clinical trials in Malaysia in order to approve the vaccine. The same goes for Pfizer vaccine. No local clinical trials will be conducted for Pfizer vaccine. Application for WHO approval of Sinopharm vaccine can only happen after the vaccine has first been approved by China's National Medical Products Administration.

@UlarSawa That is a different vaccine from China la, not Sinopharm vaccine...Of course that vaccine will need to be approved in the home country (after phase 3 trial has been completed) before it can be considered for approval by MOH.

"Health director-general Datuk Dr Noor Hisham Abdullah said the trial would be a Phase 3 clinical trial on a vaccine that has been developed by the Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS) in Beijing."

https://www.nst.com.my/news/nation/2020/12/646768/malaysias-first-covid-19-vaccine-trial-involve-3000-people

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

https://www.nst.com.my/news/nation/2020/12/646768/malaysias-first-covid-19-vaccine-trial-involve-3000-people

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/

500 million vaccine doses in Q1 2021 closer to reality, says WHO

https://www.freemalaysiatoday.com/category/world/2020/12/05/500-million-vaccine-doses-in-q1-2021-closer-to-reality-says-who/